A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Ertapenem (ERTAPENEM)

Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caus....

First FDA approval2001-11-21
Generic availableYes · 5 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$108.0M in CY2024 Part D spend264K claims · 107K beneficiaries · 329 plans surveyed

Lowest NADAC
$26.83/unit
14 NDCs benchmarked, lowest of all strengths.
Average NADAC
$29.02
Across all dosage forms in distribution.
Highest NADAC
$57.40
Range is tight.
Plans with PA
20 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Ertapenem used for?

Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caus....

Is there a generic for Ertapenem?

Yes. 5 ANDAs filed at FDA, 5 generic manufacturers currently shipping.

How much does my plan pay for Ertapenem?

Across 329 Part D plans, Ertapenem averages $29.02/unit (NADAC). Lowest available: $26.83/unit. Highest in distribution: $57.40/unit.

Is Ertapenem on the FDA shortage list?

No. Ertapenem is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Penem Antibacterial2 alternatives in D1
01
Imipenem and Cilastatin
Brand: Imipenem and Cilastatin
Lowest NADAC
2Generic mfrs
CY24 Part D spend
Compare →
02
Meropenem
Penem Antibacterial
$5.84Lowest NADAC
8Generic mfrs
$26.3MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (6 approvals on file) · NADAC unit costs: CMS NADAC weekly file (14 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.